Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114609 | 0.93 | KCNH2 (0.57) | KCNH2CYP3A4MAPTKDM4EHSD17B10 | |
| SCHEMBL8113698 | 0.93 | KCNH2 (0.57) | KCNH2CYP3A4MAPTKDM4EHSD17B10 | |
| SCHEMBL8127638 | 0.93 | KCNH2 (0.57) | KCNH2CYP3A4MAPTKDM4EHSD17B10 | |
| SCHEMBL613219 | 0.89 | KCNH2 (0.39) | KCNH2CYP2D6 | |
| SCHEMBL483300 | 0.81 | KDM4E (0.34) | KCNH2KDM4ELMNA | |
| SCHEMBL2649459 | 0.75 | ALDH1A1 (0.36) | KDM4ELMNAPOLBALDH1A1MMP2 | |
| SCHEMBL8122307 | 0.74 | KCNH2 (0.36) | KCNH2CYP3A4MAPTKDM4EHSD17B10 | |
| SCHEMBL2650824 | 0.73 | CYP2A6 (0.41) | CYP3A4LMNASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL6295153 | 0.72 | FFAR1 (0.38) | KCNH2TSHRFFAR1FFAR4ALDH1A1 | |
| SCHEMBL614578 | 0.71 | CYP1A2 (0.50) | KCNH2CYP3A4MAPTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160367639-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | disclosed |
| EP-1474163-A2 | MODIFICATION OF FEEDING BEHAVIOR | Imperial College Innovations Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003026591-A9 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1137631-B1 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE | UNIV SOUTHERN CALIFORNIA (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003057235-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2003-07-17 | — | — | WO | disclosed |
| US-6590071-B1 | Increasing the delivery of hydrophilic amine containing compounds to the cell having a mucosal barrier, in which a compound of given formula penetrates the mucosal barrier of the cell; free amine is liberated by hydrolysis | UNIVERSITY OF SOUTHERN CALIFORNIA | 2003-07-08 | — | — | US | disclosed |
| WO-2003027637-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026591-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2003-04-03 | — | — | WO | disclosed |
| EP-1137631-A1 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034236-A1 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KCNH2 1230/4885CYP3A4 2444/4885MAPT 3346/4885 |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KCNH2 1231/4885CYP3A4 2495/4885MAPT 3335/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | KCNH2 1067/4885CYP3A4 2256/4885MAPT 3347/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KCNH2 1230/4885CYP3A4 2444/4885MAPT 3346/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | KCNH2 1052/4885CYP3A4 2217/4885MAPT 3376/4885 |
| US-20160367639-A1 | MODIFICATION OF FEEDING BEHAVIOR | GLP1R, NPY4R, NPY1R | KCNH2 4416/4885CYP3A4 4805/4885MAPT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.